| Mitapivat: A Quinolone Sulfonamide to Manage Hemolytic Anemia in Adults With Pyruvate Kinase Deficiency.Am J Ther | PMID 37713687无 PMCID | 2023 Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy, Durability, and Safety of Faricimab in Patients From Asian Countries With Diabetic Macular Edema: 1-Year Subgroup Analysis of the Phase III YOSEMITE and RHINE Trials.Asia Pac J Ophthalmol (Phila) | PMID 37851562无 PMCID | 2023 Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Multiple switching between the biosimilar adalimumab PF-06410293 and reference adalimumab in patients with active rheumatoid arthritis: a phase 3, open-label, randomised, parallel-group study.Lancet Rheumatol | PMID 38251497无 PMCID | 2023-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind study.Lancet Rheumatol | PMID 38251498无 PMCID | 2023-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Phase 3 Trial of Concizumab in Hemophilia with Inhibitors.N Engl J Med | PMID 37646676无 PMCID | 2023-Aug-31 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| ACTIV-2: A Platform Trial for the Evaluation of Novel Therapeutics for the Treatment of Early COVID-19 in Outpatients.J Infect Dis | PMID 37650231PMC10469341 | 2023-Aug-31 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrant.Breast Cancer Res | PMID 37653397PMC10469877 | 2023-Aug-31 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Safety and Immunogenicity of Inactivated Whole Virion COVID-19 Vaccine CoviVac in Clinical Trials in 18-60 and 60+ Age Cohorts.Viruses | PMID 37766235PMC10537914 | 2023-Aug-29 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet | PMID 37385278无 PMCID | 2023-Aug-26 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial.Lancet | PMID 37385279无 PMCID | 2023-Aug-26 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of the anti-TNF multivalent NANOBODY® compound ozoralizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: A 52-week result of a Phase II/III study (OHZORA trial).Mod Rheumatol | PMID 36197757无 PMCID | 2023-Aug-25 | 0.45 | The study is a randomized Phase II/III trial with a drug intervention, but it is for rheumatoid arthritis (non-oncology) and does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS). | 待处理 |
| Efficacy and safety of anti-TNF multivalent NANOBODY® compound 'ozoralizumab' without methotrexate co-administration in patients with active rheumatoid arthritis: A 52-week result of phase III, randomised, open-label trial (NATSUZORA trial).Mod Rheumatol | PMID 36201360无 PMCID | 2023-Aug-25 | 0.95 | The trial is a Phase III, randomized, drug intervention study in humans with primary efficacy and safety endpoints, but it is not oncology. Therefore, it does not meet the primary requirement of being a human malignant-neoplasm trial. | 待处理 |
| Efficacy and safety of paliperidone palmitate 6-monthly long-acting injectable in reduction of relapses in patients with schizophrenia: An Asian subgroup analysis of phase 3, randomized study.Medicine (Baltimore) | PMID 37653768PMC10470698 | 2023-Aug-25 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Pitavastatin to Prevent Cardiovascular Disease in HIV Infection.N Engl J Med | PMID 37486775PMC10564556 | 2023-Aug-24 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| The Growth Hormone Deficiency (GHD) Reversal Trial: effect on final height of discontinuation versus continuation of growth hormone treatment in pubertal children with isolated GHD-a non-inferiority Randomised Controlled Trial (RCT).Trials | PMID 37605233PMC10440873 | 2023-Aug-21 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.Lancet | PMID 37385275无 PMCID | 2023-Aug-19 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Age-adjusted high-dose chemotherapy followed by autologous stem cell transplantation or conventional chemotherapy with R-MP as first-line treatment in elderly primary CNS lymphoma patients - the randomized phase III PRIMA-CNS trial.BMC Cancer | PMID 37596517PMC10436648 | 2023-Aug-18 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Long-term efficacy and safety of erenumab in Japanese patients with episodic and chronic migraine: results from a 28-week open-label treatment period of a randomised trial.BMJ Open | PMID 37597868PMC10441051 | 2023-Aug-18 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma.N Engl J Med | PMID 37272516PMC11445763 | 2023-Aug-17 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Relugolix combination therapy in European women with symptomatic uterine fibroids: a subgroup analysis from the randomized phase 3 LIBERTY pivotal trials.Gynecol Endocrinol | PMID 37634528无 PMCID | 2023-Aug-17 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study.Arthritis Res Ther | PMID 37587493PMC10428525 | 2023-Aug-16 | 0.95 | The study is a randomized, phase 3b trial with a drug intervention (guselkumab) and reports original results. However, it is not an oncology study (psoriatic arthritis) and does not include a time-to-event efficacy endpoint (e.g., OS, PFS, DFS) as a primary or key secondary outcome; the primary focus is on serum biomarkers and clinical response metrics like ACR20. | 待处理 |
| Olaparib efficacy in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer: Subgroup analyses from the phase III OlympiAD trial.Int J Cancer | PMID 36971103无 PMCID | 2023-Aug-15 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials).Am J Respir Crit Care Med | PMID 37364283PMC10449067 | 2023-Aug-15 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Envonalkib versus crizotinib for treatment-naive ALK-positive non-small cell lung cancer: a randomized, multicenter, open-label, phase III trial.Signal Transduct Target Ther | PMID 37574511PMC10423717 | 2023-Aug-14 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| A phase II dose evaluation pilot feasibility randomized controlled trial of cholecalciferol in critically ill children with vitamin D deficiency (VITdAL-PICU study).BMC Pediatr | PMID 37580663PMC10424361 | 2023-Aug-14 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial.Lancet | PMID 37423231无 PMCID | 2023-Aug-12 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy confirmation study of aceneuramic acid administration for GNE myopathy in Japan.Orphanet J Rare Dis | PMID 37568154PMC10416530 | 2023-Aug-11 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer.N Engl J Med | PMID 37272513PMC11074923 | 2023-Aug-10 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Prospective validation of VEGF and eNOS polymorphisms as predictors of first-line bevacizumab efficacy in patients with metastatic colorectal cancer.Sci Rep | PMID 37558720PMC10412588 | 2023-Aug-09 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Impact of web application support versus standard management on adherence with adjuvant hormone therapy in patients treated for breast cancer: the WEBAPPAC study.BMC Cancer | PMID 37559004PMC10413707 | 2023-Aug-09 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Efficacy of single-dose oral secnidazole for the treatment of trichomoniasis in women co-infected with trichomoniasis and bacterial vaginosis: a post hoc subgroup analysis of phase 3 clinical trial data.BMJ Open | PMID 37550019PMC10407359 | 2023-Aug-07 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study.Lancet | PMID 37423228无 PMCID | 2023-Aug-05 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| The role of triple therapy and therapy sequence in treatment of BRAF-mutant metastatic melanoma. Response to overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study.J Transl Med | PMID 37543586PMC10403899 | 2023-Aug-05 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Olanzapine With or Without Fosaprepitant for Preventing Chemotherapy Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy: A Phase III Randomized, Double-Blind, Placebo-Controlled Trial (ALLIANCE A221602).Oncologist | PMID 37284847PMC10400142 | 2023-Aug-03 | 0.80 | The trial is a Phase III randomized oncology trial in humans, but its primary efficacy outcome is the prevention of chemotherapy-induced nausea and vomiting, which does not constitute a survival, progression, recurrence, or time-to-event efficacy endpoint as defined by the adjudication criteria for Kaplan-Meier digitization. | 待处理 |
| Efficacy of subcutaneous vs intravenous infliximab in rheumatoid arthritis: a post-hoc analysis of a randomized phase III trial.Rheumatology (Oxford) | PMID 36534825PMC10393429 | 2023-Aug-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A multicenter, randomized, placebo-controlled phase IIb trial of an autologous formalin-fixed tumor vaccine for newly diagnosed glioblastomas.J Neurosurg | PMID 36670529无 PMCID | 2023-Aug-01 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Does Adjunction of Autologous Osteoblastic Cells Improve the Results of Core Decompression in Early-stage Femoral Head Osteonecrosis? A Double-blind, Randomized Trial.Clin Orthop Relat Res | PMID 36961220PMC10344543 | 2023-Aug-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer.J Clin Oncol | PMID 36977289无 PMCID | 2023-Aug-01 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| KEYNOTE-033: Randomized phase 3 study of pembrolizumab vs docetaxel in previously treated, PD-L1-positive, advanced NSCLC.Int J Cancer | PMID 37141294无 PMCID | 2023-Aug-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| An Analysis of How Herpes Zoster Pain Affects Health-related Quality of Life of Placebo Patients From 3 Randomized Phase III Studies.Clin J Pain | PMID 37166199PMC10353534 | 2023-Aug-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Multicenter Randomized Double-Blind Phase III Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer.Clin Cancer Res | PMID 37184934无 PMCID | 2023-Aug-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Immunogenicity and Safety of a Hexavalent DTwP-IPV-HB-PRP~T Vaccine Versus Separate DTwP-HB-PRP~T, bOPV, and IPV Vaccines Administered at 2, 4, 6 Months of Age Concomitantly With Rotavirus and Pneumococcal Conjugate Vaccines in Healthy Infants in Thailand.Pediatr Infect Dis J | PMID 37257121PMC10348650 | 2023-Aug-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial.J Clin Oncol | PMID 37290035PMC10419579 | 2023-Aug-01 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study.Hepatology | PMID 37386786PMC10344437 | 2023-Aug-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Race and Treatment Outcomes in Patients With Metastatic Castration-Sensitive Prostate Cancer: A Secondary Analysis of the SWOG 1216 Phase 3 Trial.JAMA Netw Open | PMID 37526936PMC10394570 | 2023-Aug-01 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Effect of Exercise on Chemotherapy-Induced Peripheral Neuropathy Among Patients Treated for Ovarian Cancer: A Secondary Analysis of a Randomized Clinical Trial.JAMA Netw Open | PMID 37526937PMC10394582 | 2023-Aug-01 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| A randomized, open-label, phase 3 study evaluating safety and immunogenicity of 13-valent pneumococcal conjugate vaccine in Chinese infants and children under 6 years of age.Hum Vaccin Immunother | PMID 37549923PMC10408693 | 2023-Aug-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Acute Kidney Injury Defined by Fluid-Corrected Creatinine in Premature Neonates: A Secondary Analysis of the PENUT Randomized Clinical Trial.JAMA Netw Open | PMID 37561461PMC10415963 | 2023-Aug-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Immunogenicity and safety of the quadrivalent inactivated split-virion influenza vaccine in populations aged ≥ 3 years: A phase 3, randomized, double-blind, non-inferiority clinical trial.Hum Vaccin Immunother | PMID 37587615PMC10438852 | 2023-Aug-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety, tolerability, pharmacodynamics and pharmacokinetics of the soluble guanylyl cyclase activator BI 685509 in patients with diabetic kidney disease: A randomized trial.Diabetes Obes Metab | PMID 37232058无 PMCID | 2023-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |